Impact of Variant Mutations on COVID-19 Testing

Like all viruses, the SARS-CoV-2 virus mutates over time, resulting in new variants. Multiple new SARS-CoV-2 variants are circulating globally, including B.1.1.7, a strain first detected in the United Kingdom and spreading in several states, and B.1.351, which recently emerged in South Africa.

While there is currently no evidence linking these new variants to more severe illness in patients, early research indicates both strains are associated with increased transmissibility, according to the Centers for Disease Control (CDC). As part of our ongoing commitment to our public health partners, ACLA members are currently working in close coordination with FDA, CDC and state and local public health labs to support research and sequencing efforts in response to these variants.

Will the sensitivity of ACLA member laboratory PCR tests be affected by these new variants?

While more research is needed to understand the public health impact of these mutations, the sensitivity of high-quality PCR assays for COVID-19, which test for multiple targets, is not expected to be affected.

Both B.1.1.7 and B.1.351 contain mutations in the Spike (S) gene. Fortunately, high-quality PCR tests, such as those offered by ACLA members, use multiple targets to test for SARS-CoV-2 and are therefore protected from significant impact.

The FDA said recently that certain tests may be impacted, but the impact does not appear to be significant. Is there reason for concern if a test uses an S-gene target?

Even if a test does utilize an S-gene target, additional targets can be used to confirm the presence of SARS-CoV-2 in an infected individual. For example, if a patient is tested with an assay that has three viral genomic targets (including one S-gene target), and the remaining two viral targets are positive, then it’s not a concern if the S-gene drops or is inconclusive. In that scenario, the patient would expect to receive a positive result. ACLA members are confident in the accuracy of our PCR test results and will continue to lead with the science.

Are ACLA members using their expertise to help sequence coronavirus genomes, or contributing to other research on the variants?

Yes, some ACLA members are supporting this effort, working in close coordination with FDA, CDC and state and local public health labs. Genetic sequencing is being used to characterize and identify a particular SARS-CoV-2 strain to support public health response.

For more information, visit aclacom